We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
The effect of a preoperative erythropoietin protocol as part of a multifaceted blood management program in daily clinical practice (CME).
- Authors
Doodeman, Hieronymus J.; Haelst, Ingrid M.M.; Egberts, Toine C.G.; Bennis, Martin; Traast, Han S.; Solinge, Wouter W.; Kalkman, Cor J.; Klei, Wilton A.
- Abstract
Background The effectiveness of a preoperative erythropoietin ( EPO) protocol to reduce allogeneic blood transfusions ( ABTs) in daily clinical practice has been insufficiently studied. This study evaluated the effect of such a protocol, as part of a multifaceted blood management program, in patients undergoing total hip arthroplasty ( THA). Study Design and Methods This retrospective observational study was designed as an interrupted time series (1999-2010). The intervention was the introduction of an EPO protocol in THA patients in 2003. Patients were classified according to preoperative hemoglobin ( Hb) level: 10 to 13 g/ dL (eligible patients for EPO) and more than 13 g/ dL. The primary outcome was the percentage of patients receiving an ABT. Segmented regression analysis was used to estimate changes in outcome after the intervention. Results A total of 4568 THA patients were included. The absolute reductions in ABTs after the intervention were 17% (95% confidence interval [ CI], 6%-29%) for the total study population and 25% (95% CI, 11%-39%) and 8% (95% CI, −5% to 21%) for the Hb groups 10 to 13 and more than 13 g/ dL, respectively. In the postintervention period, 46% of the eligible patients ( Hb level, 10-13 g/ dL) actually received EPO. The transfusion rate in the EPO group was lower compared to the non- EPO group: 14 and 50%, respectively (p < 0.01). Conclusion Introduction of a preoperative EPO protocol reduced the transfusion rate in THA patients in daily clinical practice. The reduction must be seen as part of a multifaceted blood management program, in which increased awareness of blood transfusion contributes simultaneously and substantially to the reduction in transfusion rate.
- Subjects
ERYTHROPOIETIN; BLOOD transfusion; CLINICAL trials; TOTAL hip replacement; HEMOGLOBINS; PATIENTS
- Publication
Transfusion, 2013, Vol 53, Issue 9, p1930
- ISSN
0041-1132
- Publication type
Article
- DOI
10.1111/trf.12016